Results: 3

1.
Figure 2

Figure 2. From: Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review.

Results of virologic response in different studies. PRESCO study 33% and 84%, respectively, at weeks 4 and 12 for GT-1 infections; APRICOT study 13% and 34%; PISG study 31% and 71% respectively. Similar figures for GT-2 and -3 infections were 47% and 92%, 37% and 72%, 84% and 96%, respectively.

Ashwani K Singal, et al. World J Gastroenterol. 2009 August 14;15(30):3713-3724.
2.
Figure 3

Figure 3. From: Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review.

A beneficial histological response was seen in 35% and 43%, respectively, in patients with no sustained virologic response (SVR) in the ACTG and APRICOT trials. Worsening histology was seen in 18% patients with no SVR in the APRICOT study; similar data were not available in the ACTG study. In the RIBAVIC study, histological worsening was seen in 23% without SVR while histology remained stable in the remaining patients.

Ashwani K Singal, et al. World J Gastroenterol. 2009 August 14;15(30):3713-3724.
3.
Figure 1

Figure 1. From: Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review.

Patients who consumed > 80% of their anti-HCV medications showed a trend towards better sustained virologic response (SVR) compared to those with < 80% drug compliance (72% vs 57%, P = 0.06). The SVR was much better in GT-1 infections (63% vs 34%, P = 0.008) but not in GT-2 or -3 infections (94% vs 95%, P = 0.88). Wk: Week.

Ashwani K Singal, et al. World J Gastroenterol. 2009 August 14;15(30):3713-3724.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk